|
Article Excerpt
M2 PRESSWIRE-31 December 2008-OTCPicks.com: OTCPicks.com Stocks to Watch for Wednesday, December 31st NFLD, EMAG, WSTF, BPUR(C)1994-2008 M2 COMMUNICATIONS LTD
RDATE:31122008
Our Stocks to Watch tomorrow include Northfield Laboratories Inc. (Nasdaq: NFLD), Emageon Inc. (Nasdaq: EMAG), Westaff Inc. (Nasdaq: WSTF) and Biopure Corp. (Nasdaq: BPUR).
Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.
NORTHFIELD LABORATORIES INCORPORATED (NASDAQ: NFLD) "Up 129.63% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/NFLD.php
Northfield Laboratories is a leader in developing a hemoglobin-based oxygen-carrying red blood cell substitute. The initial indication we are seeking for our investigational product PolyHeme is the treatment of life-threatening red blood cell loss when an oxygen-carrying fluid is required and red blood cells are not available. PolyHeme is a solution of chemically modified human hemoglobin that requires no cross-matching and is therefore compatible with all blood types. It has an extended shelf life in excess of 12 months.
NFLD News:
December 30 - BLA for PolyHeme Accepted for Filing and Granted Priority Review
Northfield Laboratories Inc. (Nasdaq: NFLD) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its Biologics License Application (BLA) for PolyHeme , the Company's investigative human hemoglobin-based red cell substitute for the treatment of life-threatening red blood cell loss when an oxygen-carrying fluid is required and red blood cells are not available. In addition, FDA has designated the submission for Priority Review, with a review goal date of April 30, 2009.
"Filing of our BLA for PolyHeme with Priority Review is a key milestone for Northfield," said Steven A. Gould, M.D., Chairman and Chief Executive Officer. "We are now one step closer to delivering a potential life-saving therapy to patients who need transfusion in situations when blood is not available."
Northfield announced that it had submitted the BLA for PolyHeme on October 29, 2008, based on its comprehensive development program, including data from its Multicenter Phase III randomized, double-blind trial involving 720 trauma patients. Findings from this study were presented at...
|
|
More articles from M2 Presswire
(ABAX) SqueezeTrigger Price is $15.363. There is $52,893,225.00 That S..., December 31, 2008
(ABFS) SqueezeTrigger Price is $29.384. There is $145,429,020.00 That ..., December 31, 2008
(BLL) SqueezeTrigger Price is $41.623. There is $132,790,050.00 That S..., December 31, 2008
Bulgarian Banks Aggressively Building Deposits, Flouting Economic Melt..., December 31, 2008
Michael Miller from Que Publishing and Jeremy Buck from Diskeeper to b..., December 31, 2008
Looking for additional articles?
Search our database of over 3 million articles.
Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication
name or publication date.
About Goliath
Whether you're looking for sales prospects, competitive information, company
analysis or best practices in managing your organization,
Goliath can help you meet your business needs.
Our extensive business information databases empower business
professionals with both the breadth and depth of credible,
authoritative information they need to support their business
goals. Whether it be strategic planning, sales prospecting,
company research or defining management best practices -
Goliath is your leading source for accurate information.
|
|
